Scalper1 News
Big-cap biotech Gilead Sciences (GILD) agreed Tuesday to acquire a program from small German biotech Phenex Pharmaceuticals aimed at treating liver disease. Gilead agreed to an unspecified upfront payment and milestone payments totaling up to $470 million for Phenex’s Farnesoid X Receptor program. The company press release emphasized that one of the targets of this program is non-alcoholic steatohepatitis (NASH), a common but largely untreated Scalper1 News
Scalper1 News